文献速递糖尿病

SGLT2抑制剂、GLP-1受体激动剂、DPP-4抑制剂与磺脲类对肾脏结局风险的比较有效性:基于医疗数据库的目标试验模拟

Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.
PubMed 文献 · Diabetes Care · 2020-09-16

该研究利用美国退伍军人医疗数据库,模拟目标试验,比较2型糖尿病患者启动SGLT2抑制剂、GLP-1受体激动剂、DPP-4抑制剂或磺脲类后肾脏结局风险。随访至3年,复合结局包括eGFR下降>50%、终末期肾病或全因死亡。结果显示,与磺脲类相比,SGLT2i、GLP-1和DPP-4均与较低复合结局风险相关;SGLT2i与GLP-1无显著差异,但均优于DPP-4。

要点

  • 与磺脲类相比,SGLT2i、GLP-1和DPP-4均降低肾脏复合结局风险。
  • SGLT2i与GLP-1肾脏获益无显著差异,但均优于DPP-4。
  • 各eGFR亚组中SGLT2i和GLP-1均显示一致获益。

核心结论

  • 在2型糖尿病患者中,与DPP-4抑制剂或磺脲类相比,SGLT2抑制剂或GLP-1受体激动剂治疗与较低的不良肾脏结局风险相关。

研究设计与样本

  • 研究模拟目标试验,使用美国退伍军人医疗数据库,纳入启动SGLT2i(n=18,544)、GLP-1(n=23,711)、DPP-4(n=39,399)或磺脲类(n=134,904)的2型糖尿病患者,随访至3年。

主要发现

  • 与磺脲类相比,SGLT2i、GLP-1和DPP-4的复合结局风险比分别为0.68(95%CI 0.63,0.74)、0.72(0.67,0.77)和0.90(0.86,0.95)。
  • SGLT2i与GLP-1之间风险差异无统计学意义(HR 0.95,95%CI 0.87,1.04)。
  • SGLT2i和GLP-1的复合结局风险均低于DPP-4(HR分别为0.76 [0.70,0.82]和0.79 [0.74,0.85])。
  • 按eGFR分层,与磺脲类相比,SGLT2i和GLP-1在所有eGFR类别(包括eGFR<45 mL/min/1.73 m2)均显示较低复合结局风险。
  • 与DPP-4相比,SGLT2i和GLP-1在eGFR<90至≥60、<60至≥45、<45 mL/min/1.73 m2亚组中均降低复合结局风险。

临床怎么用

  • 对于2型糖尿病伴肾脏结局风险的患者,优先考虑SGLT2i或GLP-1而非DPP-4或磺脲类可能有助于降低肾脏不良结局风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the comparative effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-1), dipeptidyl peptidase 4 inhibitors (DPP-4), and sulfonylureas on risk of kidney outcomes among people with type 2 diabetes. RESEARCH DESIGN AND METHODS: U.S. veterans initiated on SGLT2i (n = 18,544), GLP-1 (n = 23,711), DPP-4 (n = 39,399), or sulfonylureas (n = 134,904) were followed for up to 3 years to evaluate the risk of the composite outcome of estimated glomerular filtration rate (eGFR) decline >50%, end-stage kidney disease (ESKD), or all-cause mortality. Risks were estimated using survival models adjusted for predefined covariates as well as covariates identified by a high-dimensional variable selection algorithm through application of generalized propensity scores. RESULTS: Compared with those treated with sulfonylureas, treatment with SGLT2i, GLP-1, and DPP-4 was associated with a lower risk of the composite outcome (hazard ratio 0.68 [95% CI 0.63, 0.74], 0.72 [0.67, 0.77], and 0.90 [0.86, 0.95], respectively). While we did not observe a statistically significant difference in risk between the SGLT2i and GLP-1 arms (0.95 [0.87, 1.04]), both SGLT2i and GLP-1 had a lower risk of the composite outcome than DPP-4 (0.76 [0.70, 0.82] and 0.79 [0.74, 0.85], respectively). Analyses by eGFR category suggested that compared with the sulfonylurea arm, those in the SGLT2i and GLP-1 arms exhibited a lower risk of the composite outcome in all eGFR categories, including eGFR <45 mL/min/1.73 m2. Compared with DPP-4, both SGLT2i and GLP-1 exhibited a reduced risk of the composite outcome in eGFR <90 to ≥60, <60 to ≥45, and <45 mL/min/1.73 m2. CONCLUSIONS: In type 2 diabetes, treatment with SGLT2i or GLP-1 compared with DPP-4 or sulfonylureas was associated with a lower risk of adverse kidney outcomes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Xie Y, Bowe B, Gibson AK, et al. Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases. Diabetes Care. 2020. PMID: 32938746. doi:10.2337/dc20-1890

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。